Clinical Trial Update: cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria [Phase 2]

View source ↗

Summary

Phase 2 study evaluating cTACE plus sintilimab for unresectable intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED